stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) Shares outstanding
Spyre Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $64.1M, up 36.2% from $47.0M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $88.4M. Over the past ten years it has ranged from $24.0K (fiscal 2015) to $64.1M (fiscal 2025) — the current reading is the highest in ten years. Spyre Therapeutics, Inc. ranks 175th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $64.1M | 36.21% |
| FY2024 | $47.0M | 581.85% |
| FY2023 | $6.9M | 104.60% |
| FY2022 | $3.4M | 28.18% |
| FY2021 | $2.6M | 23.18% |
| FY2020 | $2.1M | 67.05% |
| FY2019 | $1.3M | 53.44% |
| FY2018 | $832.9K | 37.65% |
| FY2017 | $605.1K | 54.48% |
| FY2016 | $391.7K | 1,532.08% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $88.4M | 4.35% |
| Jun 2026 | $84.7M | 7.87% |
| Mar 2026 | $78.5M | 22.62% |
| Dec 2025 | $64.1M | 6.03% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| SYRE Spyre Therapeutics, Inc. | $88.4M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement